Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.
J Am Coll Cardiol
; 67(12): 1488-1496, 2016 Mar 29.
Article
em En
| MEDLINE
| ID: mdl-27012410
Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of their efficacy, safety, and ease of use. Both glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for glycemic control as adjuncts to metformin, other oral antiglycemic agents, or insulin. Glucagon-like peptide-1 receptor agonists may have additional effects, such as weight loss, that may be advantageous in obese patients. There is a large body of evidence from randomized controlled clinical trials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in the short term. However, concerns have been raised, particularly regarding their safety in patients with heart failure. In this review, the authors provide a brief but practical evidence-based analysis of the use of incretin-based agents in patients with diabetes, their efficacy, and cardiovascular safety.
Palavras-chave
Texto completo:
1
Coleções APS:
Guias_protocolos_manuais_internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Cardiovasculares
/
Guias de Prática Clínica como Assunto
/
Diabetes Mellitus Tipo 2
/
Incretinas
Limite:
Humans
Idioma:
En
Ano de publicação:
2016